The DOI matches its Crossref record; 101 of the 103 references it cites were found in a registry or an index.
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Open accessAbstract
The Ras-extracellular signal-regulated kinase (Ras-ERK) and phosphatidylinositol 3-kinase-mammalian target of rapamycin (PI3K-mTOR) signaling pathways are the chief mechanisms for controlling cell survival, differentiation, proliferation, metabolism, and motility in response to extracellular cues. Components of these pathways were among the first to be discovered when scientists began cloning proto-oncogenes and purifying cellular kinase activities in the 1980s. Ras-ERK and PI3K-mTOR were originally modeled as linear signaling conduits activated by different stimuli, yet even early experiments hinted that they might intersect to regulate each other and co-regulate downstream functions. The extent of this cross-talk and its significance in cancer therapeutics are now becoming clear.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“An additional layer of complexity is the cross-regulation between the two pathways with ERK signaling feeding into several nodes of PI3K/mTOR such as its phosphorylation of TSC236–38.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
Zha, J., Harada, H., Yang, E., Jockel, J., & Korsmeyer, S. J. (1996) · Cell · doi:10.1016/s0092-8674(00)81382-3 · Cited by 2,578
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244
Phosphatidylinositol-3-OH kinase direct target of Ras
Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., & Downward, J. (1994) · Nature · doi:10.1038/370527a0 · Cited by 1,954
Bonni, A., Brunet, A., West, A. E., Datta, S. R., Takasu, M. A., & Greenberg, M. E. (1999) · Science · doi:10.1126/science.286.5443.1358 · Cited by 1,908
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
Flagged first, then by citations
2 of the 103 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 901–1,000 of 1,004
Lü, X., Fu, H., Chen, R., Wang, Y., Zhan, Y.-Y., Song, G., Hu, T., Xia, C., Tian, X., & Zhang, B. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.42962 · Cited by 17
Xu, Y., Afify, S. M., Du, J., Liu, B., Hassan, G., Wang, Q., Li, H., Liu, Y., Fu, X., Zhu, Z., et al. (2022) · Scientific Reports · doi:10.1038/s41598-021-04265-w · Cited by 17
Mutti, V., Bono, F., Tomasoni, Z., Bontempi, L., Guglielmi, A., Bolognin, S., Schwamborn, J. C., Missale, C., & Fiorentini, C. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02748-z · Cited by 17
Chandran, P., Gupta, N., Retnakumari, A. P., Malarvizhi, G. L., Pavithran, K., Nair, S. V., & Koyakutty, M. (2013) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2013.04.012 · Cited by 17
Lv, Y., Xue, L., Cai, C., Liu, Q., & Shen, J. (2015) · Cell & Bioscience · doi:10.1186/s13578-015-0062-6 · Cited by 17
Holck, S., Bonde, J. H., Pedersen, H., Petersen, A. A., Chaube, A., Nielsen, H. J., & Larsson, L. (2016) · Human Pathology · doi:10.1016/j.humpath.2016.03.001 · Cited by 16
Vertical Pathway Targeting in Cancer Therapy
Shahbazian, D., Sznol, J. A., & Kluger, H. M. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00001-4 · Cited by 17
Plasma glutamate carboxypeptidase is a negative regulator in liver cancer metastasis
Lee, J., Cho, H.-S., Lee, J.-J., Jun, S. Y., Ahn, J.-H., Min, J., Yoon, J., Choi, M.-H., Jeon, S.-J., Kim, D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12967 · Cited by 17
Barrio‐Hernandez, I., Jafari, A., Rigbolt, K. T. G., Hallenborg, P., Sánchez‐Quiles, V., Skovrind, I., Akimov, V., Kratchmarova, I., Dengjel, J., Kassem, M. S., et al. (2019) · Genome Research · doi:10.1101/gr.248286.119 · Cited by 17
Unraveling the AKT/ERK cascade and its role in Parkinson disease
Keshri, P. K., & Singh, S. P. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03829-9 · Cited by 17
Deland, L., Keane, S., Bontell, T. O., Sjögren, H., Fagman, H., Øra, I., Cuesta, E. A. D. L., Tisell, M., Nilsson, J. A., Ejeskär, K., et al. (2021) · Cancer Biology & Therapy · doi:10.1080/15384047.2021.1899573 · Cited by 16
Xiao, H., Lin, S., Jiang, D., Lin, Y., Liu, L., Zhang, Q., He, J., & Chen, Y. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.654869 · Cited by 16
Lacrimal gland budding requires PI3K-dependent suppression of EGF signaling
Wang, Q., Tao, C., Hannan, A., Yoon, S., Min, X., Peregrin, J., Qu, X., Li, H., Yu, H., Zhao, J. J., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf1068 · Cited by 16
Divergent Molecular and Cellular Responses to Low and High-Dose Ionizing Radiation
Sampadi, B. K., Vermeulen, S., Mišovic, B., Boei, J. J. W. A., Batth, T. S., Chang, J.-G., Paulsen, M. T., Magnuson, B., Schimmel, J., Kool, H., et al. (2022) · Cells · doi:10.3390/cells11233794 · Cited by 18
Ma, S., Hu, Y., Chen, J., Wang, X., Zhang, C., Liu, Q., Cai, G., Wang, H., Zheng, J., Wang, Q., et al. (2023) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2023.110618 · Cited by 16
Giudice, G., Chen, H., Koutsandreas, T., & Petsalaki, E. (2024) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100771 · Cited by 16
Li, C., Li, S., Zhang, G., Li, Q., Song, W., Wang, X., Cook, J. A., van der Stoel, M. M., Wright, B. W., Altamirano, F. J., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.067606 · Cited by 17
Byun, K.-A., Lee, J. H., Lee, S. Y., Oh, S., Batsukh, S., Cheon, G. W., Lee, D., Hong, J. H., Son, K. H., & Byun, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137232 · Cited by 17
Takai, M., Nakagawa, T., Tanabe, A., Terai, Y., Ohmichi, M., & Asahi, M. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2014.1002362 · Cited by 16
Chen, Y., Tsai, Y., Lee, C., Lee, C., Chen, C., Liu, C.-M., Chen, J., Loh, S., & Tsai, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106812 · Cited by 16
Yerbes, R., López‐Rivas, A., Reginato, M. J., & Palacios, C. (2012) · Cell Death and Differentiation · doi:10.1038/cdd.2012.78 · Cited by 16
Roosan, M. R., MacNeil, S. M., Jenkins, D. F., Shrestha, G., Wyatt, S. R., McQuerry, J. A., Piccolo, S., Heiser, L. M., Gray, J. W., Johnson, W. E., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0429-x · Cited by 16
Kong, L., Wang, Q.-E., Jin, J., Xiang, Z., Chen, T., Shen, S., Wang, H., Gao, Q., & Wang, Y. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188029 · Cited by 16
Bolan, P. O., Zviran, A., Brenan, L., Schiffman, J. S., Dusaj, N. N., Goodale, A. B., Piccioni, F., Johannessen, C. M., & Landau, D. A. (2019) · Cell Systems · doi:10.1016/j.cels.2019.10.002 · Cited by 15
Possible Novel Therapeutic Targets in Lymphangioleiomyomatosis Treatment
Song, X., Cai, H., Yang, C., Xue, X., Wang, J., Mo, Y., Zhu, M., Zhu, G., Ye, L., & Jin, M. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.554134 · Cited by 16
Ribas, V. T., Vahsen, B. F., Tatenhorst, L., Estrada, V., Dambeck, V., Almeida, R. A., Bähr, M., Michel, U., Koch, J. C., Müller, H. W., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03503-3 · Cited by 17
Gorini, G., Magherini, F., Fiaschi, T., Massai, L., Becatti, M., Modesti, A., Luigi Messori, A., & Gamberi, T. (2021) · Biomedicines · doi:10.3390/biomedicines9080871 · Cited by 16
Foster, R. R., Griffin, S., Grooby, S., Feltell, R. E., Christopherson, C., Chang, M., Sninsky, J. J., Kwok, S., & Torrance, C. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045061 · Cited by 16
Tian, C., Li, L., Liang, X., He, S., Guo, W., Lv, L., Wang, Q., & Song, Y. (2016) · Genetica · doi:10.1007/s10709-016-9913-2 · Cited by 17
Shin, S., & Nguyen, L. K. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6424-6_29 · Cited by 15
Regulation of AGR2 expression via 3’UTR shortening
Matoulková, E., Sommerová, L., Pastorek, M., Vojtěšek, B., & Hrstka, R. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.04.011 · Cited by 17
Thiesen, H.-J., Steinbeck, F., Maruschke, M., Koczan, D., Ziems, B., & Hakenberg, O. W. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176659 · Cited by 16
PDK1 promotes apoptosis of chondrocytes via modulating MAPK pathway in osteoarthritis
Ge, Q., Wang, H., Xu, X., Xu, L., Zhai, L., & Tao, R. (2017) · Tissue and Cell · doi:10.1016/j.tice.2017.10.004 · Cited by 16
Kim, M. S., Park, J., Lee, E. J., Kim, S., Shin, S., Ahn, J., Jung, Y., Park, I., & Park, W. (2018) · Oncology Reports · doi:10.3892/or.2018.6689 · Cited by 16
Blanco‐Pérez, F., Goretzki, A., Wolfheimer, S., & Schülke, S. (2019) · Molecular Immunology · doi:10.1016/j.molimm.2018.12.029 · Cited by 17
Ruicci, K. M., Meens, J., Plantinga, P., Stecho, W., Pinto, N. C., Yoo, J., Fung, K., MacNeil, S. D., Mymryk, J. S., Barrett, J. W., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01713-9 · Cited by 16
Biological Function of PD-L2 and Correlation With Overall Survival in Type II Endometrial Cancer
Marinelli, O., Annibali, D., Morelli, M. B., Zeppa, L., Tuyaerts, S., Aguzzi, C., Amantini, C., Maggi, F., Ferretti, B., Santoni, G., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.538064 · Cited by 16
Challenges and Opportunities in Modeling Pancreatic CancerPreprint
Feigin, M. E., & Tuveson, D. A. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.031104 · Cited by 16
Choo, F., Odintsov, I., Nusser, K., Nicholson, K. S., Davis, L. E., Corless, C. L., Stork, L., Somwar, R., Ladanyi, M., Davis, J. L., et al. (2022) · Molecular Case Studies · doi:10.1101/mcs.a006140 · Cited by 16
Koschut, D., Ray, D., Li, Z., Giarin, E., Groet, J., Alić, I., Kham, S. K. Y., Chng, W. J., Ariffin, H., Weinstock, D. M., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01567-7 · Cited by 15
Phoswa, W. N. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.613930 · Cited by 15
Inhibitor GSK690693 extends Drosophila lifespan via reduce AKT signaling pathway
Cheng, X., Xie, M., Luo, L., Tian, Y., Yu, G., Wu, Q., Fan, X., Yang, D., Mao, X., Gaur, U., et al. (2022) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2022.111633 · Cited by 16
PKC-independent PI3K signalling diminishes PKC inhibitor sensitivity in uveal melanoma
Park, J., Hamad, S. A., Stewart, A., Carlino, M. S., Lim, S. Y., & Rizos, H. (2024) · Oncogenesis · doi:10.1038/s41389-024-00511-8 · Cited by 16
Martinez-Jaramillo, E., Jamali, F., Abdalbari, F. H., Abdulkarim, B., Jean‐Claude, B. J., Telleria, C. M., & Sabri, S. (2024) · Cancers · doi:10.3390/cancers16132319 · Cited by 15
Steroidal saponins: Natural compounds with the potential to reverse tumor drug resistance (Review)
Cui, A., Liu, H., Liu, X., Zhang, M., Xiao, B., Wang, B., & Yang, J. (2024) · Oncology Letters · doi:10.3892/ol.2024.14719 · Cited by 18
Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy
Kasper, S., Reis, H., Ziegler, S., Nothdurft, S., Mueller, A. M., Goetz, M., Wiesweg, M., Phasue, J., Ting, S. C., Wieczorek, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17438 · Cited by 16
Selvakumar, G. P., Iyer, S. S., Kempuraj, D., Ahmed, M. E., Thangavel, R., Dubova, I., Raikwar, S. P., Zaheer, S. A., & Zaheer, A. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1340-1 · Cited by 15
Wang, F., Tan, Y., Zhang, J., & Zhou, G. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.04.158 · Cited by 15
Qian, Y., Wang, Q., Jiao, J., Wang, G., Gu, Z., Huang, D., & Wang, Z. (2019) · Neurological Research · doi:10.1080/01616412.2019.1672391 · Cited by 15
REV‐ERBα activates the mTOR signalling pathway and promotes myotubes differentiation
Dadon‐Freiberg, M., Chapnik, N., & Froy, O. (2020) · Biology of the Cell · doi:10.1111/boc.201900091 · Cited by 15
Xiao, L., Shu, L., Ge, L., Qiu, S., Wan, H., Wu, S., Fei, J., Peng, S., & Zeng, X. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00530 · Cited by 15
Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma
Zhu, Q., Ren, H., Li, X., Qian, B., Fan, S., Hu, F., Xu, L., & Zhai, B. (2020) · Aging · doi:10.18632/aging.104028 · Cited by 15
Cell Populations Expressing Stemness-Associated Markers in Vascular Anomalies
Kilmister, E. J., Hansen, L., Davis, P. F., Hall, S. R. R., & Tan, S. T. (2021) · Frontiers in Surgery · doi:10.3389/fsurg.2020.610758 · Cited by 15
Guzmán, E. A., Pitts, T. P., Winder, P. L., & Wright, A. E. (2021) · Marine Drugs · doi:10.3390/md19050249 · Cited by 15
A patent review of mTOR inhibitors for cancer therapy (2011–2020)
Qiu, H., Wang, P., & Zhang, M. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1940137 · Cited by 15
Zaky, D. A., Eldehna, W. M., Kerdawy, A. M. E., Abdallah, D. M., El-Abhar, H. S., & Wadie, W. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108370 · Cited by 15
Call the Eckols: Present and Future Potential Cancer Therapies
Monteiro, P., Lomartire, S., Cotas, J., Marques, J. C., Pereira, L., & Gonçalves, A. M. M. (2022) · Marine Drugs · doi:10.3390/md20060387 · Cited by 15
Bcl-xl and Mcl-1 are the major determinants of the apoptotic response to dual PI3K and MEK blockage
Jokinen, E., & Koivunen, J. P. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3071 · Cited by 16
Gu, S., & Chen, C. (2015) · Insect Science · doi:10.1111/1744-7917.12301 · Cited by 15
Rheb may complex with RASSF1A to coordinate Hippo and TOR signaling
Nelson, N. C., & Clark, G. J. (2016) · Oncotarget · doi:10.18632/oncotarget.8447 · Cited by 15
Trairatphisan, P., Wiesinger, M., Bahlawane, C., Haan, S., & Sauter, T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156223 · Cited by 15
Inhibition of Phosphoinositide-3-Kinase Signaling Promotes the Stem Cell State of Trophoblast
Lee, C. Q. E., Bailey, A. J., López‐Tello, J., Sferruzzi-Perri, A. N., Okkenhaug, K., Moffett, A., Rossant, J., & Hemberger, M. (2019) · Stem Cells · doi:10.1002/stem.3052 · Cited by 15
eEF2K Activity Determines Synergy to Cotreatment of Cancer Cells With PI3K and MEK Inhibitors
Hijazi, M., Casado, P., Akhtar, N., Álvarez–Teijeiro, S., Rajeeve, V., & Cutillas, P. R. (2022) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2022.100240 · Cited by 14
mTORC1 syndrome (TorS): unified paradigm for diabetes/metabolic syndrome
Bar‐Tana, J. (2023) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2023.01.001 · Cited by 16
MiR-18a-5p attenuates HER2-positive breast cancer development by regulating PI3K/AKT pathway
Liu, Y., & Hua, Y. (2023) · Cancer Biology & Therapy · doi:10.1080/15384047.2023.2224512 · Cited by 14
ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer
Farmaki, E., Nath, A., Emond, R., Karimi, K. L., Grolmusz, V. K., Cosgrove, P. A., & Bild, A. (2023) · eLife · doi:10.7554/elife.85898 · Cited by 14
Cytoskeletal activation of NHE1 regulates mechanosensitive cell volume adaptation and proliferation
Ni, Q., Ge, Z., Li, Y., Shatkin, G., Fu, J., Sen, A., Bera, K., Yang, Y., Wang, Y., Wu, Y., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114992 · Cited by 14
Kuger, S., Flentje, M. P., & Djuzenova, C. S. (2015) · Radiation Oncology · doi:10.1186/s13014-015-0514-5 · Cited by 16
Aldosterone induces myofibroblast EGF secretion to regulate epithelial colonic permeability
Miró, L., Pérez‐Bosque, A., Maijó, M., Amat, C., Naftalin, R. J., & Moretó, M. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00292.2012 · Cited by 14
Decker, H., Piermartiri, T., Nedel, C. B., Romão, L. F., Francisco, S. S., Dal-Cim, T. A., Boeck, C. R., Moura‐Neto, V., & Tasca, C. I. (2019) · Purinergic Signalling · doi:10.1007/s11302-019-09677-y · Cited by 14
Landi, A., Mari, M. C., Wolf, T., Kleiser, S., Gretzmeier, C., Wilhelm, I., Kiritsi, D., Thünauer, R., Geiger, R., Nyström, A., et al. (2019) · Life Science Alliance · doi:10.26508/lsa.201900422 · Cited by 16
Identification of signature genes associated with therapeutic resistance to anti-VEGF therapy
Jaiprasart, P., Dogra, S., Neelakantan, D., Devapatla, B. K., & Woo, S. (2020) · Oncotarget · doi:10.18632/oncotarget.27307 · Cited by 14
Novel Tyrosine Kinase Targets in Urothelial Carcinoma
Torres-Jiménez, J., Albarrán-Fernández, V., Pozas, J., Román-Gil, M. S., Esteban-Villarrubia, J., Carrato, A., Rosero, A., Grande, E., Alonso-Gordoa, T., & Molina-Cerrillo, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020747 · Cited by 14
Tsui, J., Qi, S., Perrino, S., Leibovitch, M., & Brodt, P. (2021) · Biomolecules · doi:10.3390/biom11040527 · Cited by 15
Yu, F., Gajendran, B., Wang, N., Sample, K. M., Liu, W., Wang, C., Hu, A., Zacksenhaus, E., Hao, X., & Ben‐David, Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-08402-6 · Cited by 14
A new view of macula densa cell protein synthesis
Shroff, U. N., Gyarmati, G., Izuhara, A. K., Deepak, S. K., & Peti‐Peterdi, J. (2021) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00222.2021 · Cited by 14
Synergistic targeting of the PI3K/mTOR and MAPK/ERK pathways in Merkel cell carcinoma
Temblador, A., Topalis, D., Andreï, G., & Snoeck, R. (2022) · Tumour Virus Research · doi:10.1016/j.tvr.2022.200244 · Cited by 14
Amin, T., Sharma, R. P., Mir, K. B., Slathia, N., Chhabra, S., Tsering, D., Kotwal, P., Bhagat, M., Nandi, U., Parkesh, R., et al. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175945 · Cited by 14
TMEFF2 modulates the AKT and ERK signaling pathways.
Chen, X., & Ruiz-Echevarría, M. J. (2013) · Europe PMC (PubMed Central) · Cited by 14
Liu, W., Yang, H., Su, W.-C., Wang, C.-C., Chen, H., Wang, H., Huang, W., Chen, D., & Lai, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043824 · Cited by 14
Li, X., Xing, T., & Du, D. (2016) · Current Issues in Molecular Biology · doi:10.21775/cimb.020.013 · Cited by 14
Kim, Y. M., Jeon, Y. J., Huh, J., Kim, S. D., Park, K. K., & Cho, M. (2016) · Applied Biological Chemistry · doi:10.1007/s13765-016-0237-9 · Cited by 14
Jahromi, L. P., Sasanipour, Z., & Azadi, A. (2017) · Medical Hypotheses · doi:10.1016/j.mehy.2017.12.007 · Cited by 14
Arriagada, C., Luchsinger, C., González, A., Schwenke, T., Arriagada, G., Folch, H., Ehrenfeld, P., Burgos, P. V., & Mardones, G. A. (2019) · PLoS ONE · doi:10.1371/journal.pone.0212321 · Cited by 14
Iesari, S., Mocchegiani, F., Nicolini, D., Cacciaguerra, A. B., Coletta, M., Montalti, R., Mandolesi, A., Lerut, J. P., & Vivarelli, M. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15377 · Cited by 14
Спирина, Л. В., Кондакова, И. В., Тарасенко, Н. В., Slonimskaya, E. M., Usynin, E. A., Gorbunov, A. K., Yurmazov, Z. A., & Chizhevskaya, S. Y. (2018) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2018.01.09 · Cited by 14
Görgişen, G., & Yaren, Z. (2020) · Folia Neuropathologica · doi:10.5114/fn.2020.94005 · Cited by 14
Peptide inhibitors: Breaking cancer code
Coburn, F., Nsereko, Y., Armstrong, A. J., & Musaimi, O. A. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117961 · Cited by 13
Recent Developments in Targeting RAS Downstream Effectors for RAS-Driven Cancer Therapy
Tatlı, Ö., & Doğanay, G. D. (2021) · Molecules · doi:10.3390/molecules26247561 · Cited by 14
Nguyen, P., Doan, P., Murugesan, A., Ramesh, T., Rimpiläinen, T., Candeias, N. R., Yli-Harja, O. P., & Kandhavelu, M. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120307 · Cited by 13
Hung, Y.-W., Ouyang, C., Ping, X., Qi, Y., Wang, Y.-C., Kung, H., & Ann, D. (2023) · Journal of Biomedical Sciences · doi:10.1186/s12929-023-00924-4 · Cited by 12
Predicting the target landscape of kinase inhibitors using 3D convolutional neural networks
Kanev, G. K., Zhang, Y., Kooistra, A. J., Bender, A., Leurs, R., Bailey, D. S., Würdinger, T., de Graaf, C., de Esch, I. J. P., & Westerman, B. A. (2023) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1011301 · Cited by 13
Crosstalk with lung fibroblasts shapes the growth and therapeutic response of mesothelioma cells
Chrisochoidou, Y., Roy, R., Farahmand, P., Gonzalez, G., Doig, J., Krásný, L., Rimmer, E. F., Willis, A. E., MacFarlane, M., Huang, P. H., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06240-x · Cited by 14
Yang, Y., Liu, P., Jin, Y., Zhu, H., Wang, M., Jiang, X., & Gao, H. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156068 · Cited by 13
Understanding the molecular regulatory mechanisms of autophagy in lung disease pathogenesis
Lin, L., Lin, Y., Han, Z., Wang, K., Zhou, S., Wang, Z., Wang, S., & Chen, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1460023 · Cited by 13
Gao, X., Zhang, G., & Huang, L. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s146300 · Cited by 12
Of local translation control and lipid signaling in neurons
Moine, H., & Vitale, N. (2018) · Advances in Biological Regulation · doi:10.1016/j.jbior.2018.09.005 · Cited by 15
Placental Ras Regulates Inflammation Associated with Maternal Obesity
Liong, S., Barker, G., & Lappas, M. (2018) · Mediators of Inflammation · doi:10.1155/2018/3645386 · Cited by 16
4‐O‐methylascochlorin activates autophagy by activating AMPK and suppressing c‐Myc in glioblastoma
Hwang, S., Han, S., Jeong, Y., Magae, J., Bae, Y., & Chang, Y. (2020) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22552 · Cited by 13
Reißig, T. M., Sara, L., Ting, S. C., Reis, H., Metzenmacher, M., Eberhardt, W., Zaun, G., Herold, T., Aigner, C., Darwiche, K., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.09.005 · Cited by 13
Metadata
- Authors
- Mendoza, M. C., Er, E. E., & Blenis, J.
- Affiliations
- Harvard University (US)
- Corresponding author
- Blenis, John
- Venue
- Trends in Biochemical Sciences
- Publisher
- Elsevier BV
- Published
- 2011-06
- Volume
- 36
- Issue
- 6
- Pages
- 320-328
- ISSN
- 0968-0004 (ISSN-L)
- PMC
- PMC3112285
- OpenAlex
- W1998203489
- Cited by
- 1,817
- References
- 103
- Citations by year
- 2026: 112 · 2025: 96 · 2024: 122 · 2023: 133 · 2022: 127 · 2021: 163 · 2020: 166 · 2019: 164 · 2018: 144 · 2017: 158 · 2016: 123 · 2015: 100 · 2014: 92 · 2013: 55 · 2012: 49
- FWCI
- 5.82
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Trends in Biochemical Sciences (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- LAM Foundation
- Susan G. Komen
- National Cancer Institute (R37CA046595)
- National Institute of General Medical Sciences (R01GM051405)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- Ras/ERK signaling pathway, signaling crosstalk, cell survival, cell proliferation, cell differentiation, cellular metabolism, cell motility, proto-oncogenes, cancer therapeutics
- MeSH terms
- Humans, Signal Transduction, ras Proteins, Extracellular Signal-Regulated MAP Kinases, Phosphatidylinositol 3-Kinase, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review